Founders- Dr Pramod Dhembare and Dr Geeta Dhembare
Total team strength- 100
Total funds raised- Bootstrapped
Investors- Founders have invested their funds
Revenue generated since inception- Rs 14 crore (target for FY21-22)
Key Highlights-
Provides end-to-end pharmacovigilance services or customized services
Full-scale pharmacovigilance support throughout global drug life cycle
A drug safety partner for the local Indian companies looking to introduce new products in the advanced markets
First CRO in India to offer Functional Service Provider solutions to customers for their drug safety needs
To expand geographical footprint (especially in North America) to support a more global pharmacovigilance services offering
To implement Robotic Process Automation (RPA) and Artificial Intelligence (AI) technologies to automate workflow processes in pharmacovigilance
Founder Speaks-
"The strategic vision is to build an organisation at the forefront of the development of exciting new drugs and therapies and global life cycle management of these treatments while continuing to grow successfully as a global specialist in pharmacovigilance services business. Over the next five years, our primary focus will be for FHS to become the mid-sized Drug Safety CRO of choice and the market leader in this sector."
- Dr Pramod Dhembare, Founder and Managing Partner, Fidelity Health Services, Pune
